Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most general safety interaction concepts (grapefruit increasing atorvastatin concentrations; increased risk of myopathy with higher grapefruit amounts; liver function testing; mechanism as HMG-CoA reductase inhibition) align with the provided label excerpts. However, several specific claims are unsupported or over-specific (e.g., grapefruit component names, enzyme wording, quantified “up to 50%” increase, and claims about “liver damage” risk directly tied to grapefruit), and an external-source recommendation is not label-supported.
Category Scores
Accurate Statements
Grapefruit contains furanocoumarins (including bergamottin and dihydroxybergamottin) that can interact with Lipitor.
Supported in part: Section 7.2 states grapefruit juice contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
When grapefruit is consumed, its furanocoumarins inhibit the enzyme responsible for metabolizing Lipitor, leading to increased levels of Lipitor in the bloodstream.
Supported in part: Section 7.2 states grapefruit juice components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
Consuming grapefruit while taking Lipitor can lead to muscle damage.
Supported in part: Section 5.1 describes risk of myopathy/rhabdomyolysis with interacting drugs; Section 17.1 states risk of myopathy is increased when consuming larger quantities (>1 liter) of grapefruit juice.
Elevated Lipitor levels due to grapefruit juice can lead to an increased risk of muscle damage.
Supported in part: Section 7.2 links grapefruit juice to increased plasma concentrations; Section 17.1 links higher grapefruit juice quantities to increased myopathy risk.
There is no specific guideline for how much grapefruit is safe to consume with Lipitor.
Not directly stated in the provided excerpts; however, Section 7.2 provides a threshold for 'excessive grapefruit juice consumption (>1.2 liters per day)' and Section 17.1 provides '>1 liter'—there is labeling information about amounts associated with increased risk rather than a definitive safe amount.
It is generally recommended to avoid consuming grapefruit or grapefruit juice while taking Lipitor.
Supported in spirit by labeling caution: Section 7.2 warns grapefruit juice can increase plasma concentrations, and Section 17.1 notes increased risk with larger grapefruit juice quantities; the excerpts do not explicitly use blanket 'avoid' wording, but the safety messaging is consistent.
Unsupported Statements
Lipitor works by inhibiting the production of cholesterol in the liver, thereby reducing the risk of heart disease and stroke.
Partially aligns with mechanism/indications, but the claim combines an unlabeled phrasing about 'inhibiting the production of cholesterol in the liver' with a broad disease-risk causal statement. The provided label excerpts support HMG-CoA reductase inhibition (Sections 11 and 12.1) and indicate reduction in MI and stroke risk (Section 1.1), but the specific phrasing 'inhibiting production of cholesterol in the liver' is not explicitly stated in the provided excerpts.
Grapefruit contains furanocoumarins (including bergamottin and dihydroxybergamottin) that can interact with Lipitor.
Section 7.2 confirms components of grapefruit juice inhibit CYP 3A4, but the specific component names 'bergamottin and dihydroxybergamottin' are not present in the provided excerpts.
When grapefruit is consumed, its furanocoumarins inhibit the enzyme responsible for metabolizing Lipitor, leading to increased levels of Lipitor in the bloodstream.
The label excerpt specifies inhibition of CYP 3A4 (Section 7.2), not a generic 'enzyme responsible for metabolizing Lipitor.'
Consuming grapefruit while taking Lipitor can increase the risk of liver damage.
The provided excerpts link grapefruit to increased atorvastatin plasma concentrations (Section 7.2) and increased myopathy risk with larger grapefruit juice quantities (Section 17.1). They do not state grapefruit increases risk of liver damage; liver dysfunction is addressed separately via transaminase elevations and LFT monitoring (Sections 5.2 and 17.2).
Grapefruit can interact with other medications, including blood thinners, diabetes medications, and certain antibiotics.
The provided excerpts list interaction considerations including strong CYP3A4 inhibitors (Section 7.1) and provide specific interactions for clarithromycin, cyclosporine, etc., plus general grapefruit juice interaction (Section 7.2). They do not specifically mention blood thinners, diabetes medications, or 'certain antibiotics' by those classes in the provided excerpts.
A study conducted by the FDA found that consuming grapefruit juice can increase the levels of Lipitor in the bloodstream by up to 50%.
The provided excerpts mention increased plasma concentrations with grapefruit juice, especially with excessive consumption (>1.2 liters/day) (Section 7.2), but they do not provide any 'up to 50%' quantitative figure or attribute it to an FDA study.
Increased Lipitor levels due to grapefruit juice can lead to an increased risk of liver damage.
Unsupported by the provided excerpts; grapefruit-related increased concentrations are described (Section 7.2), and myopathy risk is specifically addressed with grapefruit amounts (Section 17.1), but no grapefruit-to-liver-damage risk linkage is stated.
DrugPatentWatch.com recommends that grapefruit and grapefruit juice be avoided while taking Lipitor.
External source content is not supported or referenced in the provided FDA labeling excerpts.
DrugPatentWatch.com advises patients to consult their doctor or pharmacist before consuming grapefruit or grapefruit juice while taking Lipitor.
External source content is not supported or referenced in the provided FDA labeling excerpts.
Dr. James Stein recommends that patients avoid consuming grapefruit or grapefruit juice while taking Lipitor.
External source content is not supported or referenced in the provided FDA labeling excerpts.
The article states that it is best to avoid consuming grapefruit or grapefruit juice while taking Lipitor.
External source content is not supported or referenced in the provided FDA labeling excerpts.
Contradictions
Important Omissions
FDA labeling specifies the interaction is linked to excessive grapefruit juice consumption (>1.2 liters/day) and increased myopathy risk with larger quantities (>1 liter) rather than a simple 'avoid' statement.
Importance:
Moderate
Labeling also provides that grapefruit juice components inhibit CYP 3A4; the response did not consistently and precisely attribute the mechanism to CYP 3A4.
Importance:
Moderate
Label excerpt includes liver function test recommendations prior to and at 12 weeks after initiation; the response did not mention this monitoring guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are unsupported (e.g., grapefruit increasing liver damage risk; 'up to 50%' increase; specific grapefruit component names; broad class-based interaction claims). These inaccuracies could mislead risk expectations and dosing/avoidance behaviors.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Unsupported specificity and quantitative/attribution claims about grapefruit effects (e.g., 'up to 50%', named furanocoumarins, and grapefruit-related liver damage risk) that are not present in the provided label excerpts.
Suggested Improvement
Replace external-source and numeric claims with label-supported statements: grapefruit juice inhibits CYP 3A4 and can increase atorvastatin plasma concentrations, especially with excessive consumption (>1.2 L/day), and myopathy risk is increased with larger quantities (>1 liter). Avoid claiming grapefruit specifically increases liver damage unless supported; cite label-based liver monitoring (LFTs prior to and at 12 weeks after initiation).